Rhythm Pharmaceuticals, Inc. (RYTM) is a Healthcare stock trading at $96.81 (as of 2026-06-18), with a market capitalization of $6.05B and a trailing P/E of -28.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Rhythm Pharmaceuticals, Inc. develops and commercializes therapeutics for rare genetic obesity disorders. Its lead product, IMCIVREE, targets melanocortin-4 receptor–related conditions, and it is also developing setmelanotide for multiple obesity indications linked to POMC/LEPR and other MC4R pathway disorders.